In a StoneRisk Diagnostic Profile, citric acid is one of the parameters measured to assess an individual's risk of developing kidney stones. Citric acid is a naturally occurring organic acid found in various fruits, particularly citrus fruits like oranges, lemons, and limes. It plays a vital role in kidney stone formation and prevention.
Here's how citric acid is relevant in a stone risk profile:
→ Inhibiting Stone Formation: Citric acid acts as an inhibitor of kidney stone formation. It works by binding to calcium ions in the urine, preventing them from crystallizing and forming solid deposits. This inhibitory effect helps reduce the risk of calcium-based kidney stones, such as calcium oxalate and calcium phosphate stones.
→ Maintaining Urine pH: Citric acid contributes to maintaining the urine's pH at a level that discourages the formation of stones. A more acidic urine pH is generally less conducive to stone formation, particularly for certain types of stones.
→ Promoting Solubility: Citric acid increases the solubility of various minerals in urine, making it less likely for minerals to precipitate and form crystals or stones.
A low citric acid level in the urine can indicate a reduced ability to inhibit stone formation, potentially increasing the risk of kidney stone development, especially calcium-based stones. Conversely, higher citric acid levels are generally associated with a lower risk of stone formation.
A stone risk profile typically measures various other parameters as well, including calcium, oxalate, phosphate, uric acid, and more, to provide a comprehensive assessment of an individual's risk for kidney stones. The results of these tests help healthcare providers understand the underlying factors contributing to stone formation and guide preventive strategies and treatments accordingly.
References:
Zuckerman JM, Assimos DG. Hypocitraturia: pathophysiology and medical management. Rev Urol. 2009 Summer;11(3):134-44. PMID: 19918339; PMCID: PMC2777061.
Curhan GC, Taylor EN. 24-h uric acid excretion and the risk of kidney stones. Kidney Int. 2008 Feb;73(4):489-96. doi: 10.1038/sj.ki.5002708. Epub 2007 Dec 5. PMID: 18059457.
Chow K, Dixon J, Gilpin S, Kavanagh JP, Rao PN. Citrate inhibits growth of residual fragments in an in vitro model of calcium oxalate renal stones. Kidney Int. 2004 May;65(5):1724-30. doi: 10.1111/j.1523-1755.2004.00566.x. PMID: 15086911.
Nicar MJ, Skurla C, Sakhaee K, Pak CY. Low urinary citrate excretion in nephrolithiasis. Urology. 1983 Jan;21(1):8-14. doi: 10.1016/0090-4295(83)90113-9. PMID: 6823713.
Every lab result you’ve ever had, charted and explained.
Healthmatters is a tracker for your lab results. Upload a report from any lab, any country — every marker charted and explained.
Start with my report →All our content is backed by peer-reviewed studies, academic research, and trusted medical sources. We’re committed to accuracy and transparency — see our editorial policy for details.